Scale -


  • Ebitda is 1092 Rs Cr; Annual Growth is 20 %; Continuous Growth over 3 years
  • Revenue is 2520 Rs Cr; Continuous Growth over 3 years
  • PBT is 277 Rs Cr; Continuous Growth over 3 years
  • Quarterly Ebitda is 248 Rs Cr; Continuous Growth over 3 Quarters
  • Quarterly Profit is 204 Rs Cr; Continuous Growth over 3 Quarters
  • Quarterly Revenue is 653 Rs Cr; in Bottom Quartile

Profitability -


  • PBDIT Margin is 43.34 %; Continuous Growth over 3 years; in Top Quartile
  • Quarterly Ebitda Margin is 38 %; Continuous Growth over 3 Quarters; in Top Quartile
  • PAT Margin is 28.67 %; in Top Quartile; Annual Decline is -15 %
  • Quarterly Profit margin is 31 %; in Top Quartile

Return -


  • ROCE is 24.08 %; Annual Growth is 23 %
  • ROA is 14.67 %; in Top Quartile
  • Asset Turnover is 51 %; in Bottom Quartile

Efficiency -


  • Operating cash flow is 968 Rs Cr; Annual Growth is 47 %; Continuous Growth over 3 years
  • Inventory Turnover Ratio is 5.31; Continuous Growth over 3 years; 5 Year CAGR is 61 %
  • Current Ratio is 6.06; in Top Quartile; 5 Year CAGR is 21 %
  • Quick Ratio is 5.31; in Top Quartile; 5 Year CAGR is 24 %

Solvancy -


  • Debt/Equity is 0; in Bottom Quartile
  • Total Debt is 2.5 Rs Cr; in Bottom Quartile

Quality -


  • Operating cashflow/ebitda is 89 %; Annual Growth is 23 %; Continuous Growth over 3 years; in Top Quartile
  • Operating cashflow/PAT is 134 %; Annual Growth is 56 %; Continuous Growth over 3 years
  • Exceptional Items/PBT is -5 %; Annual Decline is -130 %
  • Change in Inventories/Total Expenses is -2 %; Annual Decline is -227 %
  • Other Expenses/Total Expenses is 22 %; Continuous Decline over 3 years; in Bottom Quartile
  • Current Tax/PAT is 36 %; Continuous Growth over 3 years

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Bristol-Myers Squibb Company (BMY) Seasonal Returns Chart
Miro Sciences Ltd (MSX) analisi della leadership e del team di gestione
Pfizer Inc (Derivative) price today, PFE to USD live price, marketcap and chart
Pfizer Inc. (1PFE.MI) Seasonal returns chart
Top Players Pfizer, Roche, and GSK in the Chronic Pain Market as It
Vertigo Treatment Market Led by Pfizer, GSK and Sanofi Drive
Pfizer’s ELREXFIO Meets Primary Endpoint in Phase 3 Trial for Relapsed or Refractory Multiple Myeloma
What Could Pfizer (NYSE:PFE) Reveal About Its Next Growth Chapter?
Deal Watch: Teva Gets BioXcel Neuropsychiatric Assets In Bankruptcy Proceeding
Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients
Pfizer shares may move 3.8% on Nov. 3 earnings release By Investing.com
What Could Drive Pfizer (NYSE:PFE) Through Its Next Business Shift?
What Pfizer Holders Bought Into
Pfizer Sees Path Forward for Cancer Drug Despite Trial Failure